Figure S7 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 311K, Loss of miR-30a-3p promotes UMRC2 tumor growth</p

Figure S8 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 27K, GATA3 expression in ccRCCs</p

Figure S3 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 123K, Regulation of HIF2? by miR-30c-2-3p and miR-30a-3p in ccRCCs</p

Supplementary Data from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 162K, Methods and supplementary figure legends</p

Figure S4 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 53K, Cell proliferation modulated by miR-30c-2-3p in ccRCCs</p

Figure S2 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 42K, miR-30c-2-3p and miR-30a-3p are not regulated by HIFs</p

Figure S6 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 463K, Cell survival is reduced upon increased miR-30c-2-3p expression in RCC cells</p

Figure S1 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 84K, Genomic loci and expression of miR-30c-2-3p and miR-30a-3p in ccRCCs</p

Figure S5 from Restricted Expression of <i>miR-30c-2-3p</i> and <i>miR-30a-3p</i> in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity

PDF file 28K, miR-30c-2-3p, miR-30a-3p and HIF2? levels in stable UMRC2 cells</p

DataSheet_1_Metabolic Stress Index Including Mitochondrial Biomarker for Noninvasive Diagnosis of Hepatic Steatosis.pdf

BackgroundMitochondrial dysfunction with oxidative stress contributes to nonalcoholic fatty liver disease (NAFLD) progression. We investigated the steatosis predictive efficacy of a novel non-invasive diagnostic panel using metabolic stress biomarkers.MethodsAltogether, 343 subjects who underwent magnetic resonance imaging-based liver examinations from a population-based general cohort, and 41 patients enrolled in a biopsy-evaluated NAFLD cohort, participated in the development and validation groups, respectively. Serologic stress biomarkers were quantitated by enzyme-linked immunosorbent assay.ResultsMultivariate regression showed that waist-to-hip ratio, fibroblast growth factor (FGF) 21, FGF19, adiponectin-to-leptin ratio, insulin, albumin, triglyceride, total-cholesterol, and alanine-aminotransferase were independent predictors of steatosis (rank-ordered by Wald). The area under receiver-operator characteristics curve [AUROC (95%CI)] of the metabolic stress index for steatosis (MSI-S) was 0.886 (0.85−0.92) and 0.825 (0.69−0.96) in development and validation groups, respectively. MSI-S had higher diagnostic accuracy (78.1%−81.1%) than other steatosis indices. MSI-S notably differentiated steatosis severities, while other indices showed less discrimination.ConclusionMSI-S, as a novel non-invasive index, based on mitochondrial stress biomarker FGF21 effectively predicted steatosis. Furthermore, MSI-S may increase the population that could be excluded from further evaluation, reducing unnecessary invasive investigations more effectively than other indices.</p